System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Multicenter Study Epublish

PubMed: 42839349 DOI: 10.2340/actadv.v106.adv-2026-0765

Efficacy and Safety of Delgocitinib and Its Impact on Patient's Perspective for Moderate-to-severe Chronic Hand Eczema in Adults: A 16-week Real-world Prospective Multicentre Study.

Acta Derm Venereol 106

Authors: Elena Pezzolo, Raul Armando Luyo Saboya, Michela Ortoncelli, Simone Ribero, Federica Gelato, Marco Galluzzo, Marina Talamonti, Edoardo Mortato, Antonio Costanzo, Luigi Gargiulo, Alessandra Narcisi, Matteo Bianco, Carlotta Gurioli, Gionathan Orioni, Camilla Loi, Niccolò Gori, Ketty Peris, Elena Ippoliti, Giampiero Girolomoni, Martina Maurelli, Maria Esposito, Sara Triolo, Caterina Foti, Giorgia Sbarra, Ersilia Tolino, Nevena Skroza, Andrea Carugno, Nicola Zerbinati, Anna Balato, Eugenia Veronica Di Brizzi, Martina Burlando, Vito Di Lernia, Pietro Morrone, Emiliano Antiga, Maria Concetta Fargnoli, Filomena Russo, Francesca Caroppo, Laura Fagotto, Piergiacomo Calzavara-Pinton, Stefano Bighetti, Mariateresa Rossi

Affiliations

  • Department of Dermatology, San Bortolo Hospital, Vicenza, Italy.
  • Department of Dermatology, San Bortolo Hospital, Vicenza, Italy.
  • Dermatologic Clinic, Department of Medical Science, University of Turin, Turin, Italy.
  • Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy; Dermatology Unit, Azienda Ospedaliera Universitaria "Policlinico Tor Vergata", Rome, Italy.
  • Dermatology Unit, Azienda Ospedaliera Universitaria "Policlinico Tor Vergata", Rome, Italy.
  • Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
  • Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
  • Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.
  • ele, Milan, Italy, 7Dermatology Unit, IRCCS Azienda OspedalieroUniversitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy, 8Section of Dermatology, University Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, Italy; Unit of Dermatology, Department of Medical and Surgical Sciences, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy.
  • 8Section of Dermatology, University Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, Italy; Unit of Dermatology, Department of Medical and Surgical Sciences, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy.
  • Section of Dermatology, University Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, Italy; Unit of Dermatology, Department of Medical and Surgical Sciences, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy.
  • Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
  • Unit of Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
  • Unit of Dermatology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, Bari, Italy.
  • Dermatology Unit "Daniele Innocenzi", Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Rome, Italy.
  • Dermatology Unit, Department of Medicine and Surgery, University of Insubria, Varese, Italy.
  • Dermatology Unit, University of Campania L. Vanvitelli, Naples, Italy.
  • Section of Dermatology, Department of Health Sciences (DiSSal), University of Genoa, Genoa, Italy; Dermatology Unit, IRCCS San Martino University Hospital, Genoa, Italy.
  • Dermatology Unit, Arcispedale Santa Maria Nuova, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Provincial Health Authority of Cosenza, Cosenza, Italy.
  • Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy.
  • Scientific Direction, IRCCS San Gallicano, Dermatological Institute, Rome, Italy.
  • Department of Dermatology Unit, Istituto Dermopatico dell'Immacolata - Istituto di Ricovero e Cura a Carattere Scientifico (IDI-IRCCS), Rome, Italy.
  • Pediatric Dermatology Regional Center, Department of Women and Children's Health (SDB), University of Padua, Padua, Italy; Dermatology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
  • Institute of Dermatology, Santa Maria della Misericordia University Hospital, Udine, Italy.
  • Dermatology Department, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy.

Abstract

Delgocitinib is a pan-Janus kinase inhibitor approved for moderate-to-severe chronic hand eczema (CHE) in adults. However, real-world evidence remains limited. We prospectively evaluated 149 adult patients (mean age: 46.4 years; 60.4 % female) treated with delgocitinib for chronic hand eczema across 20 Italian dermatology centres between May and November 2025, with a four-month follow-up. Two-thirds of patients were non-occupationally exposed, and>80% had vesicular or atopic chronic hand eczema. At week 4, Physician Global Assessment (PGA)-chronic hand eczema 0/1 and Hand Eczema Severity Index (HECSI)-75 were achieved in 42.3% and 43.8% of patients, increasing significantly to 74.3% and 88.0% at week 16. Pruritus and pain Numerical Rating Scale (NRS) 0/1 were reported in 43.8% and 52.3% of patients at week 4, rising significantly to 74.4% and 86.5% at week 16. Hand Eczema Symptom Diary-Patient Global Impression of Severity (HESD PGI-S) 0/1 increased from 45.6% to 76.6%. Non-occupationally exposed patients showed significantly higher early response rates than occupationally exposed, with attenuation of differences by week 16. HECSI-75 responses were consistent across chronic hand eczema subtypes, particularly vesicular (94.0%) and atopic (90.0%). Treatment was well tolerated, with rare and no severe adverse events reported. These findings support delgocitinib as a rapid, effective and safe treatment option for chronic hand eczema.

MeSH

Safety, Eczema